Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Galmed Pharmaceuticals stock (GLMD)

Buy Galmed Pharmaceuticals stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

Galmed Pharmaceuticals is a biotechnology business based in the US. Galmed Pharmaceuticals shares (GLMD) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $3.12 – an increase of 2.3% over the previous week. Galmed Pharmaceuticals employs 3 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Galmed Pharmaceuticals stock

Top pick for advanced traders

Go to site
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

Our pick for investing by theme

Go to site
  • Trade $0 commission stocks & ETFs with as little as $1
  • Earn up to $300 with qualifying deposits
  • Discover new opportunities with Opto's AI-driven thematic investing system
  • Theme and ETF screener

Our pick for stock bonuses

Go to site
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options with no options contract fees
  • Get up to $1,000 in stock when you fund a new account within 30 days
  • Complimentary access to a financial planner
Probability of member receiving $1,000 is 0.028%

How to buy Galmed Pharmaceuticals stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – GLMD. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Galmed Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 4 of 4
Product USFST Finder Score Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
Finder score
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
$0
$0
N/A
Get $50-$5,000
Finder score
Stocks, ETFs
$0
$0
N/A
Earn up to $300
Finder score
Stocks, Options, Mutual funds, ETFs, Alternatives
$0
$0
0.02%
Get up to $1,000 in stock
Finder score
Stocks, Bonds, Options, ETFs, Cryptocurrency, Alternatives, Treasury Bills, High-yield cash account
$0
$0
4.35%
Get up to $10,000 and transfer fees covered
loading

What is the Finder Score?

The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.

We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.

Read the full Finder Score breakdown

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Galmed Pharmaceuticals stock price (NASDAQ: GLMD)

Use our graph to track the performance of GLMD stocks over time.

Galmed Pharmaceuticals shares at a glance

Information last updated 2024-12-26.
Latest market close$3.12
52-week range$2.56 - $15.10
50-day moving average $3.22
200-day moving average $4.05
Wall St. target price$12.00
PE ratio 0.0436
Dividend yield N/A
Earnings per share (TTM) $69.72

Is it a good time to buy Galmed Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Galmed Pharmaceuticals price performance over time

Historical closes compared with the close of $3.04 from 2024-12-24

1 week (2024-12-20) -0.33%
1 month (2024-11-27) 6.29%
3 months (2024-09-27) -57.12%
6 months (2024-06-27) 1,032.64%
1 year (2023-12-27) 590.91%
2 years (2022-12-27) -96.87%
3 years (2021-12-27) 343.8
5 years (2019-12-27) 1027.8002

Is Galmed Pharmaceuticals stock undervalued or overvalued?

Valuing Galmed Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Galmed Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Galmed Pharmaceuticals's P/E ratio

Galmed Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 0x. In other words, Galmed Pharmaceuticals shares trade at around 0x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Galmed Pharmaceuticals financials

Gross profit TTM $0
Return on assets TTM -29.31%
Return on equity TTM -52.67%
Profit margin 0%
Book value $33.01
Market Capitalization $5 million

TTM: trailing 12 months

Galmed Pharmaceuticals share dividends

We're not expecting Galmed Pharmaceuticals to pay a dividend over the next 12 months.

Have Galmed Pharmaceuticals's shares ever split?

Galmed Pharmaceuticals's shares were split on a 1:12 basis on 29 August 2024 . So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Galmed Pharmaceuticals shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Galmed Pharmaceuticals shares which in turn could have impacted Galmed Pharmaceuticals's share price.

Galmed Pharmaceuticals share price volatility

Over the last 12 months, Galmed Pharmaceuticals's shares have ranged in value from as little as $2.56 up to $15.1. A popular way to gauge a stock's volatility is its "beta".

GLMD.US volatility(beta: 0.8)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Galmed Pharmaceuticals's is 0.798. This would suggest that Galmed Pharmaceuticals's shares are less volatile than average (for this exchange).

Galmed Pharmaceuticals overview

Galmed Pharmaceuticals Ltd. , a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma.

Frequently asked questions

null
What percentage of Galmed Pharmaceuticals is owned by insiders or institutions?
Currently 1.286% of Galmed Pharmaceuticals shares are held by insiders and 0.485% by institutions.
How many people work for Galmed Pharmaceuticals?
Latest data suggests 3 work at Galmed Pharmaceuticals.
When does the fiscal year end for Galmed Pharmaceuticals?
Galmed Pharmaceuticals's fiscal year ends in December.
Where is Galmed Pharmaceuticals based?
Galmed Pharmaceuticals's address is: 16 Abba Hillel Road, Ramat Gan, Israel, 5250608
What is Galmed Pharmaceuticals's ISIN number?
Galmed Pharmaceuticals's international securities identification number is: IL0011313900
What is Galmed Pharmaceuticals's CUSIP number?
Galmed Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: M47238106

More guides on Finder

Ask a question

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site